Trials / Terminated
TerminatedNCT04276376
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w |
| DRUG | Rucaparib | Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID |
Timeline
- Start date
- 2019-04-12
- Primary completion
- 2023-01-25
- Completion
- 2023-12-12
- First posted
- 2020-02-19
- Last updated
- 2025-12-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04276376. Inclusion in this directory is not an endorsement.